Medical News Today (Free subscription) | 05/09/2008
Sepracor Inc. (Nasdaq: SEPR) announced the presentation of LUNESTA ® brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona.
Business Wire (Free subscription) | 03/09/2008
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of
WorkAtHome (Free subscription) | 03/09/2008
MARLBOROUGH, Mass.—-Sepracor Inc. today announced the presentation of LUNESTA® brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology Congress in Barcelona.
Contract Pharma Breaking News (Free subscription) | 20/08/2008
Richard Ranieri has been appointed to the newly created position of executive vice president, Human Resources and Administration, and Julio Casoy, M.D. has been appointed senior vice president, Medical Affairs, at Sepracor . Mr. Ranieri joins the company from Neurocrine Biosciences, where he was senior vice president and chief administrative officer. Mr. Ranieri managed and directed the company’s...
Business Wire (Free subscription) | 19/08/2008
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced the appointment of two senior managers to key strategic and
Seeking Alpha (Free subscription) | 31/07/2008
Sepracor Inc. (SEPR) Q2 FY08 Earnings Call Complete Story »
WBJournal.com (Free subscription) | 29/07/2008
Marlborough-based pharmaceutical company Sepracor Inc. said it saw second quarter revenue increase 6.3 percent to $294 million.
The Boston Business Journal (Free subscription) | 29/07/2008
A tax benefit helped Sepracor Inc. report a big boost in net income for its second quarter, but increased competition and changing government regulations prompted the company to offer mixed guidance for the remainder of the fiscal year.
Market Watch (Free subscription) | 29/07/2008
Drug stocks climb in early action while shares of Sepracor Inc. tumble after it issues a disappointing 2008 financial forecast.
Market Watch (Free subscription) | 29/07/2008
BOSTON (MarketWatch) -- Drug stocks climbed in early action Tuesday while shares of Sepracor Inc. tumbled after it issued a disappointing 2008 financial forecast. The Amex Pharmaceutical Index advanced 0.8% to 304.8 and the Amex Biotechnology Index rose 1.1% to 833.3. Sepracor shares sank 14% to $17.52. The pharmaceutical company said it now sees 2008 revenue coming in between $1.28 billion and $1.38...
Forbes (Free subscription) | 29/07/2008
The pharma company's ''improvement drugs'' fail to improve its Q2 earnings.
Seeking Alpha (Free subscription) | 28/07/2008
Sepracor (SEPR) is expected to report Q2 earnings before market open Tuesday, July 29, with a conference call scheduled for 8:30 am ET. Guidance Analysts are looking for a profit of 23c on revenue of 303.55M. The consensus range for EPS is wide, 5c to 50c, with a revenue range of $269.59M to $326.32M, according to First Call. Complete Story »
EuroInvestor.co.uk (Free subscription) | 25/07/2008
Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter 2008 financial results on July 29, 2008. In conjunction with the press release, Sepracor will host a conference call and l.. - Read more
Business Wire (Free subscription) | 14/07/2008
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced its intention to fully support the
Contract Pharma Breaking News (Free subscription) | 30/06/2008
Galapagos NV's service division, BioFocus DPI , will provide compound management and related services to Sepracor for a total contract value of $1.5 million. Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor's compound library, and plate and replicate these compounds for three years. Services will be provided by BioFocus DPI's compound...
